J. Biol. Chem., Vol. 275, Issue 24, 18302-18310, June 16, 2000
Do Structural Deviations between Toxins Adopting the Same
Fold Reflect Functional Differences?*
Alejandro
Ricciardi
§,
Marie-Hélène
le Du¶,
Mounira
Khayati¶,
Federico
Dajas
,
Jean-Claude
Boulain¶,
André
Ménez¶, and
Frédéric
Ducancel§¶
From the
Instituto de Investigaciones Biologicas,
Clemente Estable, Montevideo, Uruguay 11600 and the
¶ Département d'Ingénierie et d'Etudes des
Protéines, Commissariat à l'Energie Atomique, CE Saclay,
91191 Gif-sur-Yvette Cedex, France
Received for publication, September 24, 1999, and in revised form, December 17, 1999
 |
ABSTRACT |
Three-finger proteins form a structurally related
family of compounds that exhibit a great variety of biological
properties. To address the question of the prediction of functional
areas on their surfaces, we tentatively conferred the
acetylcholinesterase inhibitory activity of fasciculins on a
short-chain curaremimetic toxin. For this purpose, we assimilated the
three-dimensional structure of fasciculin 2 with the one of toxin
.
This comparison revealed that the tips of the first and second loops,
together with the C terminus residue, deviated most. A first
recombinant fasciculin/toxin
chimera was designed by transferring
loop 1 in its entirety together with the tip of loop 2 of fasciculin 2 into the toxin
scaffold. A second chimera (rChII) was obtained by
adding the point Asn-61
Tyr substitution. Comparison of functional and structural properties of both chimeras show that rChII can accommodate the imposed modifications and displays nearly all the
acetylcholinesterase-blocking activities of fasciculins. The three-dimensional structure of rChII demonstrates that rChII adopts a
typical three-fingered fold with structural features of both parent
toxins. Taken together, these results emphasize the great structural
flexibility and functional adaptability of that fold and confirm that
structural deviations between fasciculins and short-chain neurotoxins
do indeed reflect functional diversity.
 |
INTRODUCTION |
Three-fingered folded proteins are abundant in venoms of Elapid
and hydrophiid snakes, and are capable of performing a large number of
refined highly toxic functions (1). Snake toxins with such a fold are
usually classified as short-chain toxins, with about 60 residues and 4 disulfide bonds, and as long-chain toxins, with ~70 residues and 5 disulfide bonds. Typical members of three-fingered toxins include
short-chain curaremimetic toxins (2), long-chain curaremimetic toxins
(3, 4), which block peripheral nicotinic acetylcholine receptors,
neurotoxins (5, 6), which act on neuronal receptors, muscarinic toxins,
which activate or block muscarinic receptors (7), and fasciculins, which inhibit acetylcholinesterases (8-10). The abundant literature on
the structures of three-fingered toxins indicates that their fold is
composed of a globular core with four disulfides and three fingers that
emerge from the core. It has been suggested that the primary function
of the core is to maintain the overall structure of this family of
toxins (11, 12), whereas a structural plasticity is perceived at the
level of the loops (13). The latter might allow functional residues in
different active toxins to adopt a variety of arrangements to recognize
their targets (14, 15). Close inspection of individual three-finger
structures reveals that they display marked differences from one toxin
to another, indicating that this fold can indeed accommodate some
deviations. Thus, the first loop is longer in short-chain than in
long-chain curaremimetic toxins, and long-chain toxins possess an extra
loop cyclized by a disulfide bond localized at the very tip of the central loop (2). In muscarinic toxins, the tip of the central loop is
more twisted than in a short-chain curaremimetic toxins (7). The
orientations of the loops relative to the plane defined by the sheet
characteristic of three-fingers toxins can also vary from one toxin to
another (15). Finally, the fold acts as a monomer in most toxins or as
a dimer in neuronal toxins. It is currently speculated that these
structural deviations reflect distinct functions, and indeed this
hypothesis recently received some support. Thus, it has been
demonstrated that the capacity of long-chain curaremimetic toxins to
recognize the
7-type neuronal acetylcholine receptor
with high affinity, is depending on the presence of an extra cyclic
loop at the tip of their central loop (16).
The aim of this paper was to explore the possibility that other
structural deviations, more subtle than the presence of a cluster of
additional residues, could also reflect the localization of a
particular functional topography. To investigate this hypothesis, we
searched for structural deviations between two functionally unrelated
three-fingered toxins: a short-chain curaremimetic toxin that blocks
acetylcholine receptors (17), and a fasciculin known as
acetylcholinesterase blocker (18). The biological determinants of these
two toxins were recently shown to be located within the same area of
the three finger fold but on opposite faces (15). An exhaustive
mutational analysis revealed that a short-chain neurotoxin recognizes
the nicotinic acetylcholine receptor via a homogenous and
polar surface of 10 residues located on one face of the toxin (19, 20).
In contrast, the three-dimensional structures of two fasciculin 2 AChE1 complexes revealed a
three point anchorage forming a large contact area located on the other
face of the toxin and involving a majority of main-chain/side-chain
hydrophobic interactions (21, 22).
We investigated the possibility of generating acetylcholinesterase
inhibitory activity within the host curare-like toxin
through the
progressive transfer of the most structural deviating regions from
fasciculin 2. We show that the host protein cannot only accommodate the
imposed structural modifications but also that the biological activity
of the host short-chain toxin vanished, whereas nearly all the
acetylcholinesterase-blocking activities of fasciculins emerged in a
chimeric protein. The three-dimensional structure of the most active
chimeric compound we engineered reveals a typical three-finger fold
among which only transferred regions adopt a fasciculin-like
conformation. Taken together, these results strongly suggest that
structural deviations and functional topographies are intimately linked
to each other. They also emphasize the great structural flexibility and
functional adaptability of the three-finger fold. We propose this
approach as a convenient alternative to systematic mutations in
predicting a functional determinant at the surface of a toxin adopting
a three-fingered scaffold. The evolutionary implications of these
findings will be discussed.
 |
EXPERIMENTAL PROCEDURES |
Genetic Constructions--
DNA fragments encoding recombinant
fasciculin 1 (rFas1) and chimeric T
/Fas proteins, named rChI and
-II, were cloned into the bacterial expression vector pCP (23) and
expressed as fusion proteins with two synthetic IgG binding domains
derived from protein A (24). Extremities of the cDNA encoding
fasciculin 1 were conveniently modified by polymerase chain reaction
amplification to allow its orientated cloning. The synthetic genes
encoding the two chimera were derived from that initially built to
express the native toxin
from Naja nigricollis (23)
using the primary structures of native toxin
and fasciculin 2 (Fig.
1A). Briefly, the strategy for assembling the genes was as
follows: first, 100 pmol of 12 complementary oligonucleotides with
sizes ranging from 17 to 48 bases, covering both strands and using high
frequency codons in Escherichia coli, were
annealed together; second, semisynthetic genes were generated after
ligation together of the three N and C terminus cassettes,
respectively, and third, semisynthetic genes were gel-purified and
covalently associated. The cDNA and the two synthetic genes have at
their 5'-extremities a KpnI restriction site followed by a
sequence encoding residues Asp-Asp-Asp-Asp-Lys specifically recognized
by the bovine enterokinase. Two tandem stop codons TAA and a
BamHI restriction site were created de novo at
the 3'-extremities (Fig. 1B). Finally, correctness of these constructions was checked by DNA sequencing of both strands.
Expression and Purification of Fused
Proteins--
E. coli BL21(DE3)LysS was used as a host
strain for the expression of ZZ-Fas1 and ZZ-T
/Fas I and II. For this
purpose, an overnight culture of freshly transformed cells was used to
inoculate 500 ml of tryptic soy broth (Difco, Detroit, MI) supplemented with glucose (5 g/liter), ampicillin (200 mg/l), and chloramphenicol (30 mg/l). Induction of hybrids production was initiated by the addition of 0.1 mM (final concentration)
isopropyl-
-D-thiogalactopyranoside when the optical
density of the culture incubated at 37 °C under aeration reached
0.5-0.6 at 600 nm. After 3 h of induction
(A600 = 1.8-2.0), cells were harvested by
centrifugation, resuspended in 50 ml of TSE buffer (30 mM
Tris-HCl, 20% sucrose, 5 mM EDTA, pH 8) supplemented with
0.1 mM of phenylmethylsulfonyl fluoride (final
concentration), and disrupted by sonication at 0 °C, 5 × 3 min
at 60% of full power. The supernatant was first purified on an
IgG-Sepharose 4B-column (Amersham Pharmacia Biotech) according to
Drevet et al. (23). Lyophilized hybrids eluted from the IgG column were further purified by chromatography on a reverse-phase HPLC
column (Vydac, C4 semipreparative) equilibrated in 0.1%
trifluoroacetic acid. Elution was performed using a 0.1%
trifluoroacetic acid/CH3CN/H2O gradient of
0-60% in 60 min. Protein concentration was determined spectrophotometrically, based on the following calculated extinction coefficients at 278 nm:
M = 6200, 7500, and 8800 cm
1 for ZZ-ChI, -ChII, and -Fas1, respectively.
Bovine Enteropeptidase Cleavage and Renaturation of Recombinant
Proteins--
1 mg of ZZ fusion protein purified as described above
was combined with bovine enteropeptidase (Invitrogen, EKMax grade,
specific activity = 8.500 units/ml) in 50 mM Tris, pH
8, 10 mM CaCl2, 1% Tween-20, in a total volume
of 0.83 ml, at an enzyme:substrate ratio of 1:19,000 (w/w) and
incubated at 37 °C for 3 h. Resulting rFas1 or T
/Fas
chimeras were directly chromatographed on a reverse-phase column
(Vydac, C18) using the following gradient: 0-5 min in
0.1% trifluoroacetic acid, 5-30 min to reach 24% of
CH3CN, 10 min in trifluoroacetic acid,
0.1%/CH3CN 24%, and finally 40-70 min to obtain 60% of
CH3CN. Products were analyzed on 20% polyacrylamide gel
and submitted to amino acid composition and Edman degradation for
peptide sequencing. In vitro renaturation of unfolded
proteins was performed overnight at room temperature in a final volume of 1 ml using the following buffer: 0.1 M phosphate buffer,
pH 8, containing 4 mM GSH and 2 mM GSSG.
Refolded compounds were finally purified using conditions similar to
those previously described. The dichroic spectra of refolded compounds
were recorded at 20 °C using a CD VI Jobin-Yvon dicrograph, at a
protein concentration of 5 × 10
5 M.
Radioimmunoassay and Inhibitory Activities--
The
radioimmunoassays were carried out as described previously using
3H-labeled toxin
and two toxin-specific monoclonal
antibodies, i.e. M
1 and M
2-3
(25). Electrophorus electricus electroplax acetylcholinesterase (EeAChE) and human butyrylcholinesterase were used
to assess the inhibitory activities of rFas1, rChI, and rChII. AChE
activities were spectrophotometrically measured using acetylthiocholine
(1.0-0.06 mM) as substrate and 0.3 mM 5,5'-dithiobis(2-nitrobenzoic acid) as chromophore in 50 mM
phosphate buffer, pH 7.5, 0.1 mg/ml BSA (26). Assay mixtures (including the different inhibitors) were preincubated for 60 min at 37 °C before starting the reaction by the addition of acetylthiocholine. Ki values of rChII and native fasciculin 2 were
estimated from Dixon plots as previously reported (27-29). The lower
Ki value of rChI was estimated from slopes and
intercepts of reciprocal 1/v Lineweaver-Burk plots versus
various chimera I concentrations. Human BChE activities were assayed in
50 mM phosphate buffer, pH 7.5, 0.1 mg/ml BSA at 37 °C
with butyrylthiocholine (BTCh) as substrate, after a preincubation of
10 min. Hydrolysis of 1 mM BTCh was followed
spectrophotometrically. Type and inhibition constants of BuChE for
recombinant chimera II were determined either using Dixon plots 1/v
versus inhibitor concentration or according to
Cornish-Bowden (30) by plotting S/v against S, at three BTCh
concentrations: 0.13, 0.25, and 0.50 mM.
 |
RESULTS |
Structural Characteristics of Short-chain Curaremimetic Toxins and
Fasciculins--
To examine the structural homogeneity of these two
toxin families, we compared the x-ray three-dimensional structures of
representative members using the iterative program ALIGN (31).
Curaremimetic toxins clearly form a homogenous structural family, with
a calculated average r.m.s. c
deviation value of 1.2 Å. However,
the tips of loop 1 (residues 7-12), of loop 2 (residues 29-35), and
the two C-terminal residues deviate by between 3 and 5 Å (not shown). It is noteworthy, that six of the ten functional residues forming the
toxic site of this famility of toxins are located in the two most
variable regions (19, 20). It has been suggested that the flexibility
of the tip of loops 1 and 2 is necessary to fit the nicotinic
acetylcholine receptor (32).
Fasciculin 1 and 2 from the venom of the green mamba Dendroaspis
angusticeps are two potent inhibitors of acetylcholinesterases (8)
whose high resolution three-dimensional structures have been solved
using x-ray crystallography (9, 10). Their amino acid sequences differ
only by a single substitution at position 47, where a tyrosine or an
asparagine is found in fasciculin 1 and 2, respectively (33).
Superimposition of their backbones reveals r.m.s. c
deviation values
mostly comprised between 0.3 and 2 Å. Only residues 6-13 of loop 1 have distinct conformations with r.m.s. deviations ranging between 2 and 10 Å (not shown). It has been proposed that this unusual loop
flexibility might be important in the binding to AChEs. Interestingly,
elucidation of the x-ray structures of two fasciculin 2 AChE complexes
shows that the conformation of the free fasciculin 2 resembles that of
the bound state and differs from that of free fasciculin 1 (21, 22).
Taken together, these data support the idea that loop 1 in fasciculins
displays considerable mobility, which is important for tight binding to
AChEs. The identification of interacting residues at the tip of loop 1 further emphasizes its functional importance. Even if characterized by
a similar fold, curaremimetic toxins and fasciculins therefore possess
a number of specific structural features.
Structural Deviations between Short-chain Curaremimetic Toxins and
Fasciculins--
To identify precisely the regions where these
structural deviations occur, we carried out a detailed structural
comparison of toxin
from Naja nigricollis, a typical
member of short-chain toxins (34, 35), and fasciculin 2. Though both
toxins possess 61 residues, toxin
and fasciculin 2 each differ by a
specific insertion, which causes a numbering shift from position 18 that is only restored at position 56 (see Fig.
1). Using the iterative program ALIGN, we
performed a superimposition of the backbone of the x-ray structure of
fasciculin 2 and toxin
(Fig. 2,
lower views), revealing an average r.m.s. deviation of 2.82 Å for 226 of the 244 atom pairs of the backbone used. The best
superimpositions include most of the major
-sheet strands: 3-5,
14-17, 23-26, 34-41, and 49-55, together with the turn linking
loops 2 and 3, and the upper part of loop 3, which includes residues
56-60. However, distances greater than 2.0 Å were observed for
regions 5-12, 18-21, 27-34, 41-47, 50, 55-56, and 61 (Fas
numbering). Therefore, the regions with the largest structural
deviations between toxin
and fasciculin 2 correspond to almost all
of the first loop, the following turn, the lower part of the second
loop, and the C terminus residue. Interestingly, except for segment
18-21, the functional residues of these two molecules are included in
these areas. That segment 18-21 did not superimpose well is not
surprising because it corresponds to the turn connecting loops 1 and 2, where the additional proline +18 in toxin
is located. The deviating
region 5-12 forms a
-hairpin at the tip of loop 1 of both toxins.
However, their primary structures are totally different resulting in
highly distinct organizations in the two toxins, the hairpin looks
longer in toxin
and broader in fasciculin 2 (Fig. 2). Amino acid
residues 27-34 constitute the largest deviating region with a maximum
distance of 12 Å for c
31. This second
-hairpin
localized at the extremity of the central loop displays opposite
orientations in the two toxins, inducing an inversion of their overall
concavity (Fig. 2). Thus, the fine comparison of the structures adopted
by fasciculin 2 versus toxin
reveals three significant
structural deviating regions corresponding to the tips of loops 1 and 2 together with residue 61.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 1.
A, sequences of the natives toxin from N. nigricollis and fasciculin 2 from D. angusticeps and the newly designed toxin /Fas2 chimera.
Cysteine residues are underlined. The additional proline
residue between toxin and chimera as compared with fasciculin 2 is
bold. Substituted residues are in italic.
Asterisks indicate the two cis-prolines found in fasciculin
2. B, deduced amino acid and designed nucleotide sequences
encoding the toxin /Fas2 chimera II. The position of the 12 oligonucleotides is shown by bold slashes. Substituted
sequences are underlined. Numbering refers to amino acid
positions. 5'- and 3'-KpnI and BamHI
half-restriction sites used for cloning are shown. The enterokinase
recognition sequence and stop codons are indicated in thick
and bold characters, respectively. C, sequence
alignment of fasciculin 2 (Fas 2), rChII (Chim),
and toxin (Tox ). Residues of rChII provided from
fasciculin 2 are in yellow. Residues of rChII provided from
toxin are in blue. Residues conserved between fasciculin
2, toxin , and rChII are in green.
|
|

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 2.
Monographic comparison (upper
panels) and superposition (lower panels) in
ribbon representation of the three-dimensional structures of toxin (blue) and fasciculin 2 (yellow). Characteristic -sheets are indicated
as large arrows. The two models were superimposed by using
the topologically equivalent C S contained in the
three-stranded -sheet. Differences in loop 1 organization and loop 2 orientation are shown on the front (lower left) and 90°
rotated (lower right) views, respectively.
|
|
Design of Chimeric Proteins--
A first chimera (ChI) was
designed by transferring in toxin
the two major deviating regions
5-12 and 27-34 from fasciculin 2 (Fig. 1). As deduced from the above
comparison plus the sequence alignment, these two sequences belong to
the first and second loops. Moreover, it is known that the adjacent
residues of an amino acid sequence region are often critical for this
stretch to adopt the expected secondary structure (36). In addition, the structure superimposition revealed conserved residues surrounding the deviating regions (Fig. 1), possibly playing the role of hinges to
naturally accommodate the transferred segments into the host toxin.
Therefore, to preserve both the
-sheet and the loop flexibility, we
transferred the loop 1 in its entirety, together with residues 27-37
(toxin
numbering) in the first construction (Fig. 1). To further
attenuate the structural deviations between the two toxin
conformations, we designed a second chimeric construction (Fig. 1). In
the latter, we additionally substituted the C-terminal asparagine
residue of toxin
for a tyrosine. This was motivated by the
observation that within the complex formed with AChE, the C terminus of
Fas2 is stabilized by Tyr-4, inducing a substantial increase of the
interface (21). By doing this, we anticipated that all residues
involved in the stabilizing intramolecular hydrogen bonding between
both loops 1 and 2 and the C terminus of native fasciculin 2 may be
correctly transferred. We therefore designed two recombinant chimeric
proteins, rChI and rChII, by substituting into toxin
41 and 42, 6%
of fasciculin 2 residues, respectively. Among the 45 remaining amino
acid residues of rChII, 13, the four pairs of cysteine residues,
Tyr-23, Arg-37, Gly-38, Pro-42, and Asn-59, have been described as
forming the core responsible for the common three-fingered architecture
(13), 15 are specific to short-chain curaremimetic toxins, and 21 are
common to both toxin families.
Production, Folding, and Purification of Recombinant Fasciculin 1, rChI, and rChII--
Three reasons motivated our choice to express
fasciculin 1 instead of 2 as reference for this study. First, prior to
this work we cloned the cDNA encoding fasciculin 1 (33); second, both AChE inhibitors display very similar biological activity (8); and
third, the single difference between fasciculin 1 and 2 is located at
position +47, a region of short-chain origin within the two chimera we
designed. Recombinant native fasciculin 1 and chimera I and II were
produced within the bacterial cytoplasm fused to two synthetic IgG
binding domains (24). This recombinant system was previously proved to
be highly efficient for producing small proteins rich in disulfide
bonds (23) and recently to generate recombinant toxoids (37). It offers
the double advantage of maintaining hybrids in a soluble form and
rendering their purification from bacteria lysates easy by IgG affinity
chromatography. Fig. 3, lanes
2 and 3, shows an SDS-polyacrylamide gel
electrophoresis analysis of an IgG-Sepharose eluted fraction of a
lysate obtained from bacteria transformed with plasmids encoding the
fused chimera I or II, revealing identical profiles. Each IgG-purified
recombinant ZZ-chimera appears as a major band, migrating with an
apparent molecular mass close to the expected 24 kDa. A similar value
was noted for the ZZ-Fas1 hybrid (not shown). Furthermore, the ZZ-Fas1 or ZZ-chimera hybrids were stable in the bacterial cytoplasm because no
low molecular weight product was detected on the gel (Fig. 3). After an additional purification step
on reverse-phase HPLC chromatography, 70-90 mg of ZZ-fusion toxins
were obtained/liter of bacterial culture, which is about 100 times
higher than yields achieved using the secretion vector pEZZ18 (19,
38-41).

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 3.
SDS-polyacrylamide gel electrophoresis
analysis of recombinant chimera production, cleavage, and
purification. Crude bacterial extract of BL21(DE3)LysS transformed
by pCPZZ/ChII (lane 1). ZZ-ChI or -II hybrids after IgG
chromatography purification (lanes 2 and 3,
respectively). Crude enterokinase cleavage profil of purified ZZ-ChII
hybrid (lane 4). Reverse phase HPLC-purified recombinant
chimera II (lane 5). High molecular mass (H)
markers were: 97, 66, 45, 31, 21.5, and 14.4 kDa (Bio-Rad). Low
molecular mass (L) markers were: 16.9, 14.4, 8.2, 6.2, and
2.5 kDa (Amersham Pharmacia Biotech).
|
|

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 4.
Inhibition of E. electricus
AChE. The inhibition induced by different inhibitors was
measured after 60 min at 37 °C as described under "Experimental
Procedures." Data points correspond to duplicates that differed by
less than 5%. , fasciculin 1; , recombinant fasciculin 1; ,
fasciculin 2; , chimera II; , chimera I; , unfolded chimera
II.
|
|
The presence of two methionine residues at positions +2 and +33 or +34
in native fasciculin 1 or rChI and -II, respectively, excluded the use
of CNBr to cleave ZZ hybrids as described previously (42, 43). To
circumvent this problem, we introduce the recognition sequence
"DDDDK" for the bovine enteropeptidase, which cleaves specifically
after the P1 lysine residue (44). However, because of
problems of efficiency and specificity of cleavage probably because of
the presence of contaminating serine proteases, we finally used a
cloned bovine enterokinase catalytic subunit, an enzyme described as
having a higher specific activity (45). As a result, cleavages of
recombinant ZZ fusion proteins were achieved almost to completion,
whatever the toxin moiety. This is illustrated in the case of chimera
II in Fig. 3 (lane 4), where two major products are visible
with an apparent molecular mass of 14 and 7-8 kDa, corresponding to
those expected for the ZZ domains and cleaved chimera, respectively.
The recombinant proteins were purified by reverse-phase HPLC, leading
to a homogeneous moiety as shown in Fig. 3 (lane 5).
Sequencing of the first 15 amino acid residues and amino acid analysis
of the recombinant proteins, confirmed the specificity of the cleavage
and the absence of any side product (not shown). On average, we
obtained 10-14 mg of each cleaved and purified recombinant
protein/liter of bacterial culture.
Owing to the strategy of expression, disulfides bridges of unfolded
native or recombinant fasciculin 1 and chimeric recombinant polypeptides were formed in vitro using similar redox
conditions. The most appropriate conditions to refold reduced native
fasciculin 1 (nFas1) required a ratio of 4 GSH:2 GSSG. Under these
conditions, the refolded fasciculin 1 recovered full inhibitory
activity toward acetylcholinesterase (not shown), whereas its reduced
and carboxymethylated form was inactive. The same conditions were found
to be most appropriate for the rFas1 and both chimeric proteins. No
further improvement was seen in the presence of enzymatic catalysts
such as protein disulfide isomerase, alone or in combination with
thioredoxin (data not shown). No free thiol group was detected in
either recombinant product, using Ellman reagent, indicating that the 8 cysteines were involved in disulfide bridges. We noted no difference
between the refolding capacities of the recombinant fasciculin 1 and
the chimera as compared with the native fasciculin 1. It is noteworthy that the refolding conditions we used are opposite to those used to
refold toxin
(23), with GSSG/GSH ratios of 2/4 versus
4/2, respectively. This was surprising, because rChI and -II contain the globular core where the disulfides of toxin
, a region which has
been several times associated with conformational features of the
short-chain three-fingered fold and in particular with its folding rate
efficiency, are located (46). This suggests that the role played by the
upper part in the folding of short-chain toxins might be influenced by
sequence variations in the two first loops, and/or that at least one of
the four intramolecular disulfide bonds within these three recombinant
compounds might be characterized by a higher redox potential.
Secondary Structure, Antigenic, and Functional Properties of
Recombinant Fas 1 and Chimeras I and II--
Refolded recombinant
fasciculin 1 and chimeras I and II display similar far-UV CD spectra
indicating that they have similar secondary structures, which are
absent in reduced/carboxymethylated rChII (not shown). Furthermore, the
simultaneous presence of a positive band around 197 nm and a negative
one at 215 nm, both absent in denatured chimera II, strongly suggests
that the dominant
-sheet structure characterizing the
three-finger-like fold was present in the two recombinant chimeric
proteins. Native toxin
, which naturally interacts with high
affinity with the nicotinic acetylcholine receptor (47), is also
specifically recognized by two anti-short-chain neurotoxins: monoclonal
antibodies called M
1 (48) and M
2-3 (49).
However, the molecular topographies recognized on the surface of
short-chain neurotoxins by M
1 (50), M
2-3
(51), and the receptor (19, 20, 51) have been deeply altered to design
rChI and -II. Thus, as expected, competition binding experiments with
tritiated toxin
demonstrated that in contrast to the wild-type
toxin
, neither of the two chimera was able to bind anymore to
either monoclonal antibodies or to the acetylcholine receptor, even at
concentration as high as 10 µM (not shown).
Fig. 4 shows the inhibition patterns of AchE from EeAChE by increasing
concentrations of nFas1 and -2, rFas1, and rChI and -II. More
precisely, the data demonstrate that: i) rFas1 has a similar inhibitory
activity as compared with nFas1 or nFas2; ii) rChI inhibits hydrolysis
of acetylthiocholine with an IC50 value approximately
150-fold higher than that of native fasciculins; iii) rChII is only
15-fold less potent that native fasciculins; and iv)
reduced/carboxymethylated rChII has virtually no activity at
concentrations nearly four orders of magnitude greater than the lowest
active concentration of native fasciculin. To gain a more precise view
of the relative potencies of these compounds that act as tight
inhibitors (28), the data have been represented in typical Dixon (Fig.
5) and Lineweaver-Burk (Fig.
6) plots. The Ki
values thus calculated are respectively equal to 5500, 680, 38, and 42 pM for rChI, rChII, rFas1, and
native fasciculin 2. Lineweaver-Burk representations (Fig. 6) also
demonstrate that chimeras I and II are noncompetitive inhibitors of
EeAChE, suggesting that both compounds bind to the peripheral site of the enzyme as do native fasciculins (29). Finally, we studied the
effects of our two recombinant chimeras on hydrolysis of BTCh by human
butyrylcholinesterase. As shown in Fig.
7, upper panel, human
butyrylcholinesterase was inhibited dose dependently by rChI and rChII
in the micromolar range, with an IC50 value slightly increased as compared with nFas2. The type of inhibition of human BuChE
by the most potent chimera rChII, and its constant, were determined
according to the methods of Dixon (27) and Cornish-Bowden (30). The
intersection points of the plots of S/v (Fig. 7, lower left
panel) or 1/v (Fig. 7, lower right panel), as a
function of varying concentrations of rChII, reflect the dissociation
constants of the EI complex (Ki) and ternary complex
ESI (Ki'), respectively. We therefore conclude that
rChII is a mixed or a noncompetitive inhibitor of human
butyrylcholinesterase with Ki and
Ki' values of 1.27 and 1.13 µM,
respectively. These results are in agreement with those reported by
others (52).

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 5.
Dixon plots with data from E. electricus AChE inhibition by native fasciculin 2 and
recombinant chimera II. Activities were measured in 1-ml reaction
mixtures containing 50 nM phosphate buffer, pH 7.5, 0.1 mg/ml BSA, and 0.32 mM 5,5'-dithiobis(2-nitrobenzoic acid),
after preincubation with the inhibitor for 60 min at 37 °C.
Hydrolysis of 1 mM acetylthiocholine was followed
spectrophotometrically as described under "Experimental
Procedures." Data points correspond to duplicates that differed by
less than 5%. V/2, V/3, etc. indicate the points in the curve
corresponding to the inhibitor concentration giving one-half,
one-third, etc. of the enzyme activity measured without inhibitor.
Dixon plots of rChII (A) and nFas2 (B) are
shown.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 6.
Lineweaver-Burk plots of E. electricus AChE at different concentrations of recombinant
chimera II (A) and I (B), as
indicated with acetylthiocholine. Data points represent the
average value of two to three measurements differing by less than
5%.
|
|

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 7.
Upper panel, inhibition of human BuChE
by native fasciculin 2 and recombinant chimeras I and II. Activities
were measured in 1-ml reaction mixtures containing 50 mM
phosphate buffer, pH 7.5, 0.1 mg/ml BSA, after preincubation with the
inhibitor for 10 min at 37 °C. Hydrolysis of 1 mM of
BTCh was followed spectrophotometrically as described under
"Experimental Procedures." , fasciculin 2; , chimera II; and
, chimera I. Lower left panel, Cornish-Bowden plots for
inhibition of human BuChE by chimera II. The activity was assayed in 50 mM phosphate buffer, pH 7.5, 0.1 mg/ml BSA, with BTCh
(0.1-0.5 mM) as substrate, and the incubation time was 10 min at 37 °C. The reactions were followed by the method of Ellman
et al. (26), after the addition of the substrate.
Lower right panel: Dixon plots 1/v versus chimera
II for inhibition of human BuChE at different fixed concentrations of
BTCh. The activity was assayed in the same conditions as mentioned in
the Cornish-Bowden plots.
|
|
Structural Analysis of rChII--
In agreement with the results
provided by circular dichroism, rChII adopts a typical three-fingered
fold (Fig. 8). Indeed, the
three-dimensional structure of rChII clearly demonstrates that most of
its
-sheet regions and disulfides superimpose well on those of
fasciculin 2 and/or toxin
(Fig. 8). Interestingly, the
three-dimensional structure of rChII appears as a combination of
specific structural features of fasciculins and short-chain toxins
(53). For instance, loop 1 perfectly superimposed on loop 1 of
fasciculin 2, as well as loop 2. In contrast, regions 16-21 and 55-57
are typically toxin
, with the presence of an additional proline in
position 18 and a deletion between residues 56 and 57 in rChII. These
two regions keep within the chimera a toxin
fold. Finally, loop 3 has a toxin
sequence but its conformation is probably triggered by
the loop 2 orientation. It therefore appears that the nature of the
sequence of loop 2 affects the overall conformation of the second
-sheet. Interestingly, the part of loop 3 that corresponds to a
fasciculin 2 fold is surrounded by two glycine residues at positions 39 and 48, respectively. This confirms the assumptions made concerning the
need to preserve both the consensus sequences, which characterized the
three-fingered fold, together with the secondary structure and loop
organization typical of fasciculins. It also, emphasizes the great
structural flexibility of that fold and how neatly the host toxin
can structurally accommodate the imposed modifications. The detailed
structural analysis of recombinant chimera II is presented and
discussed in Le Du et al. (53). The coordinates of the rChII
model have been deposited to the Protein Data Bank with entry code
1qm7.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 8.
Monographic views in ribbon representation of
the three-dimensional structures of (a) toxin (blue), (b) fasciculin 2 (yellow), and (c) recombinant chimera
II. Residues conserved between fasciculin 2, toxin , and rChII
are in green. Characteristic -sheets are indicated as
large arrows.
|
|
 |
DISCUSSION |
Structural Deviations versus Functional Differences--
The aim
of this paper was to explore the possibility that within a structurally
related family of proteins, i.e. three-fingered toxins from
snakes, subtle structural deviations could reflect the localization of
a particular functional topographies. Clearly, our results strongly
support that idea. Indeed, the fasciculin regions initially identified
as differing most of toxin
(r.m.s. deviations comprised between 2 and 13 Å) have now been neatly superimposed within rChII with an
r.m.s. deviation less than 0.5 Å when compared with fasciculin 2 (53).
Thus, loop 1 in its entirety now adopts the fold it displays in native
fasciculins characterized in particular by longer
-sheets and great
mobility, because it occupies within rChII the conformation described
for free fasciculin 2, which is also that of the bound state.
Similarly, transferred residues 27-37 (toxin
numbering) from loop
2 of fasciculins not only superimposed on the structure they have in native fasciculins but also constrained the conformation of adjacent residues. Finally, the typical inverse orientation of the tip of the
central loop in fasciculins is found in rChII, which displays an
opposite concavity to toxin
. These data are in total agreement with
the recent elucidation of the structure of the complex formed between
AChE showing that: i) AChE and Fas conformations in the complex are
very similar to those of their isolated structures; ii) the high
affinity of Fas for AChE is because of a remarkable surface
complementarity involving many residues specific to fasciculins; iii)
the first loop is responsible for the particular capacity of
fasciculins to bind at the peripheral anionic site onto the surface of
AChE; iv) loop 2 enters the AChE gorge because of its particular shape
and orientation, allowing in particular an unusual stacking interaction
between Met-33 (Fas) and Trp-279 (AChE), and finally that the
C-terminal residues makes contact with the enzyme (21, 22).
Major structural deviations between short-chain neurotoxins and
fasciculins clearly reflect their difference of biological activities.
It has been recently shown that a more limited transfer of 7 of the 11 residues forming the curaremimetic site of toxin
within a similar
-sheet of charybdotoxin failed to generate a potent curaremitic
agonist, mostly for conformational reasons (54). Therefore, to respect
the structural integrity of the functional regions, we transferred
42.6% of specific residues (26 of 61 amino acid residues) from
fasciculins into toxin
mostly spread over two homogenous areas,
i.e. loop 1 and half of the central loop. Thus, our results
demonstrate that the structural deviations between short-chain
neurotoxins and fasciculins and the location of their functional sites
are intimately related. Indeed, substitution of structurally different
regions actually confers on the host scaffold the expected biological
activity, these heterologous segments containing most of the
functionally important residues as experimentally identified, and
transferred stretches keeping their native fold. This constitutes with
the
/
scorpion motif (55) a second example of the stability,
structural flexibility, and functional adaptability of animal toxins,
which are promising host scaffolds for protein engineering. Finally, we
propose the identification of structure-based features as a convenient
alternative way of guiding systematic mutations in the mapping of a
functional epitope at the surface of biologically unrelated toxins
adopting the same fold.
Evolutionary and Structural Considerations--
The choice of a
short-chain curaremimetic as host scaffold was not arbitrary. We
focused our study on three-fingered toxins whose target is a
macromolecule, which is naturally recognized by the neurotransmitter
acetylcholine. These toxins include short- and long-chain curaremimetic
toxins, which block muscular nicotinic acetylcholine receptors,
neuronal or muscarinic toxins, which act on neuronal or muscarinic
receptors, respectively, and fasciculins, which inhibit
acetylcholinesterases. Various studies suggest that these toxins are
evolutionarily related (56), and a number of observations support the
idea that they are derived from a curaremimetic toxin ancestor (57).
Therefore, curaremimetic toxins and especially short-chain neurotoxins
appeared as most plausible hosts to design three-fingered toxins with
functionally distinct behaviors. Recent experimental data show that a
long-chain neurotoxin, whose characteristic fifth disulfide bond was
selectively reduced, behaves like a short-chain toxin in terms of
specificity of receptor recognition (16). Furthermore, the addition of
a fifth disulfide bound at the tip of the central loop of a short chain
toxin increases its very low affinity for neuronal receptor (58).
Similarly, our results demonstrate that a short-chain toxin can adopt
mostly through "loop grafting," a totally unrelated biological
activity toward a distinct target, and that this functional acquisition
is structurally and functionally compatible with a conserved core of a
different origin. Taken together, these data lend further support to
the idea of an ancestor role of short-chain toxins in the phylogeny of
three-fingered proteins.
Functional Properties of Recombinant Chimera--
Newly designed
Tox
/Fas 2 recombinant chimeric molecules, and especially rChII,
display biological properties and specificities that mimic almost
completely those exhibited by native fasciculins. Recombinant chimeras
I and II differ only by the point substitution: Asn or Tyr at position
+61, respectively. However, despite this small difference, rChI is
characterized by a 10 times lower inhibitory constant than rChII toward
EaAChE. Our results confirm the importance played by the third point of
contact between Fas and AChE, which involves a tyrosine cluster
constituted of Tyr-4 and Tyr-61 side chains (21, 22) incomplete in
chimera I, because the C-terminal Tyr-61 of fasciculins was missing.
The C-terminal Tyr (conserved in fasciculins, but rare in other
three-fingered toxins) is a structurally important residue involved in
the position and orientation of the loops forming the functional site
of Fas, resulting in an enlargement of the surface area of contact of
loop II at the entrance of the AChE gorge. This strengthens the
position of the loops of fasciculin 2 at the peripheral anionic site of
the enzyme, leading to the sterical occlusion of the catalytic site.
Finally, the C-terminal region of fasciculin 2 is stabilized by
hydrogen bonds between the structurally important residue Arg-24 and
the carbonyl atom of Tyr-61. Thus, the ten times lowest inhibitory activity of rChI toward EeAChE versus rChII confirms the
structural and/or functional role played by the C terminus tyrosine
residue in fasciculins. However, the significant noncompetitive
inhibitory capacity nevertheless displayed by rChI toward EeAChE,
together with its ability to inhibit human butyrylcholinesterase,
strongly suggests that Tyr-61 most probably affects the affinity and
not the specificity of these inhibitors for acetylcholinesterases.
Recombinant chimera II and native fasciculins display very similar but
not identical biological properties. This is unlikely to be because of
the strategy of bacterial expression and in vitro renaturation that may account for that situation, because rFas1 and
denatured/renatured nFas1 have indistinguishable properties. Despite
the simultaneous presence in rChII of the three major points of
interaction previously described between fasciculin 2 and AChEs, rChII
displays a slightly lower Ki value. Among the
different explanations that may account for this, it has been
postulated that the tip of the third loop in fasciculins (especially
Asn-47 and Leu-48), establish an intramolecular interaction with the
tip of loop 2 and could also be in close contact upon complexing with
acetylcholinesterases (21, 22). It is noteworthy, that this region
adopts an intermediate conformation in chimera II, as compared with
toxin
or fasciculin 2 (53). To assess the possibility that this
remaining structural deviation could account for the weaker inhibitory
capacity of rChII, a third chimera, in which the amino acid residues of
the extremity of the third loop of Fasc 2 have been transferred, is
being studied.
 |
ACKNOWLEDGEMENTS |
We thank S. Pinkasfeld and Dr. F. Bouet for
technical assistance and N-terminal sequencing. We also thank Dr. E. Quéméneur, and Dr. S. Zinn-Justin for their help and
fruitful discussion. We are indebted to Dr. C. Cervenansky (Instituto
de Investigaciones Biologicas, Clemente Estable, Montevideo, Uruguay)
for his assistance.
 |
FOOTNOTES |
*
This work was supported in part by Evaluation-Orientation de
la Coopération Scientifique, Program de Coopération
Scientifique avec l'Uruguay.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The atomic coordinates and structure factors (code 1qm7) have
been deposited in the Protein Data Bank, Research Collaboratory for
Structural Bioinformatics, Rutgers University, New Brunswick, NJ
(http://www.rcsb.org/).
§
To whom correspondence should be addressed. Tel.: 33 1 69 08 8154;
Fax: 33 1 69 08 9071.
 |
ABBREVIATIONS |
The abbreviations used are:
AChE, acetylcholinesterase;
rFas, recombinant fasciculin;
Fas, fasciculin;
HPLC, high pressure liquid chromatography;
EeAChE, E.
electricus electroplax acetylcholinesterase;
BSA, bovine serum
albumin;
BTCh, butyrylthiocholine;
BuChE, butyrylcholinesterase;
r.m.s., root mean square;
ChI/II, chimera I/II;
rCh, recombinant Ch;
nFas, native Fas.
 |
REFERENCES |
| 1.
|
Ménez, A.
(1993)
Pour la Science
190,
34-40
|
| 2.
|
Endo, T.,
and Tamiya, N.
(1991)
in
Snake Toxins
(Harvey, A. L., ed)
, pp. 165-222, Pergamon Press, New York
|
| 3.
|
Walkinshaw, M. D.,
Saenger, W.,
and Maelicke, A.
(1980)
Proc. Natl. Acad. Sci. U. S. A.
77,
2400-2404[Abstract/Free Full Text]
|
| 4.
|
Betzel, C.,
Lange, G.,
Pal, G. P.,
Wilson, K. S.,
Maelicke, A.,
and Saenger, W.
(1991)
J. Biol. Chem.
266,
21530-21536[Abstract/Free Full Text]
|
| 5.
|
Oswald, R. E.,
Sutcliffe, M. J.,
Bamberger, M.,
Loring, R. H.,
Braswell, E.,
and Dobson, C. M.
(1991)
Biochemistry
30,
4901-4909[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Dewan, J. C.,
Grant, G. A.,
and Sacchettini, J. C.
(1994)
Biochemistry
33,
13147-13154[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Ségalas, I.,
Roumestand, C.,
Zinn-Justin, S.,
Gilquin, B.,
Ménez, R.,
Ménez, A.,
and Toma, F.
(1995)
Biochemistry
34,
1248-1260[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Cervenansky, C.,
Dajas, F.,
Harvey, A. L.,
and Karlsson, E.
(1991)
in
Snake Toxins
(Harvey, A. L., ed)
, pp. 303-321, Pergamon Press, New York
|
| 9.
|
Le Du, M. H.,
Marchot, P.,
Bougis, P. E.,
and Fontecilla-Camps, J. C.
(1992)
J. Biol. Chem.
267,
22122-22130[Abstract/Free Full Text]
|
| 10.
|
Le Du, M. H.,
Housset, D.,
Marchot, P.,
Bougis, P. E.,
Navaza, J.,
and Fontecilla-Camps, J. C.
(1996)
Acta Crystallogr. Sec. D
52,
87-92[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Brown, L. R.,
and Wütrich, K.
(1992)
J. Mol. Biol.
227,
1118-1135[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Hatanaka, H.,
Oka, M.,
Kohda, D.,
Tate, S.,
Suda, A.,
Tamiya, N.,
and Inagaki, F.
(1994)
J. Mol. Biol.
240,
155-166[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Albrand, J. P.,
Blackledge, M. J.,
Pascaud, F.,
Hollecker, M.,
and Marion, D.
(1995)
Biochemistry
34,
5923-5937[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Ménez, A.,
Bontems, F.,
Roumestand, C.,
Gilquin, B.,
and Toma, F.
(1992)
in
The Advancement of Drug Discovery
(Harvey, A. L., ed)
, pp. 83-103, Royal Society of Edinburg
|
| 15.
|
Ohno, M.,
Ménez, R.,
Ogawa, T.,
Danse, J. M.,
Shimohigashi, Y.,
Fromen, C.,
Ducancel, F.,
Zinn-Justin, S.,
Le Du, M. H.,
Boulain, J. C.,
Tamiya, T.,
and Ménez, A.
(1998)
Prog. Nucleic Acid Res. Mol. Biol.
59,
307-364[Medline]
[Order article via Infotrieve]
|
| 16.
|
Servent, D.,
Winckler-Dietrich, V.,
Hu, H. Y.,
Kessler, P.,
Drevet, P.,
Bertrand, D.,
and Ménez, A.
(1997)
J. Biol. Chem.
272,
24279-24286[Abstract/Free Full Text]
|
| 17.
|
Chang, C. C.
(1979)
in
Snake Venoms, Handbook of Experimental Pharmacology
(Lee, C. Y., ed), Vol. 52
, pp. 309-376, Springer-Verlag, Berlin
|
| 18.
|
Rodriguez-Ithuralde, D.,
Silveira, R.,
Barbeito, L.,
and Dajas, F.
(1983)
Neurochem. Int.
5,
267-274
|
| 19.
|
Pillet, L.,
Trémeau, O.,
Ducancel, F.,
Drevet, P.,
Zinn-Justin, S.,
Pinkasfeld, S.,
Boulain, J. C.,
and Ménez, A.
(1993)
J. Biol. Chem.
268,
909-916[Abstract/Free Full Text]
|
| 20.
|
Trémeau, O.,
Lemaire, C.,
Drevet, P.,
Pinkasfeld, S.,
Ducancel, F.,
Boulain, J. C.,
and Ménez, A.
(1995)
J. Biol. Chem.
270,
9362-9369[Abstract/Free Full Text]
|
| 21.
|
Bourne, Y.,
Taylor, P.,
and Marchot, P.
(1995)
Cell
83,
503-512[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Harel, M.,
Kleywegt, G. J.,
Ravelli, R. B. G.,
Silman, I.,
and Sussman, J. L.
(1995)
Structure
3,
1355-1366[Medline]
[Order article via Infotrieve]
|
| 23.
|
Drevet, P.,
Lemaire, C.,
Gasparini, S.,
Zinn-Justin, S.,
Lajeunesse, E.,
Ducancel, F.,
Pinkasfeld, S.,
Courçon, M.,
Trémeau, O.,
Boulain, J. C.,
and Ménez, A.
(1997)
Protein Expression Purif.
10,
293-300[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Nilsson, B.,
Moks, T.,
Jansson, B.,
Abrahmsen, L.,
Elmbllad, A.,
Holmgren, E.,
Henrichson, C.,
Jones, T. A.,
and Uhlen, M.
(1987)
Protein Eng.
1,
107-113[Abstract/Free Full Text]
|
| 25.
|
Boulain, J. C.,
Ménez, A.,
Couderc, J.,
Faure, G.,
Liacopoulos, P.,
and Fromageot, P.
(1982)
Biochemistry
21,
2910-2915[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Ellman, G. L.,
Courtney, K. D.,
Andres, V.,
and Featherstone, R. M.
(1961)
Biochem. Pharmacol.
7,
88-95[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Dixon, M.
(1972)
Biochem J.
129,
197-202[Medline]
[Order article via Infotrieve]
|
| 28.
|
Karlsson, E.,
Mbugua, P. M.,
and Rodriguez-Ithurralde, D.
(1984)
J. Physiol. (Paris)
79,
232-240[Medline]
[Order article via Infotrieve]
|
| 29.
|
Duran, R.,
Cervenansky, C.,
Dajas, F.,
and Tipton, K.
(1994)
Biochim. Biophys. Acta
1201,
381-388[Medline]
[Order article via Infotrieve]
|
| 30.
|
Cornish-Bowden, A.
(1974)
Biochem J.
137,
143-144[Medline]
[Order article via Infotrieve]
|
| 31.
|
Satow, Y.,
Cohen, G. H.,
Padlan, E. A.,
and Davies, D. R.
(1986)
J. Mol. Biol.
190,
593-604[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Guenneugues, M.,
Drevet, P.,
Pinkasfeld, S.,
Gilquin, B.,
Ménez, A.,
and Zinn-Justin, S.
(1997)
Biochemistry
36,
16097-16108[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Ducancel, F.,
Bouchier, C.,
Tamiya, T.,
Boulain, J. C.,
and Ménez, A.
(1991)
in
Snake Toxins
(Harvey, A. L., ed)
, pp. 385-414, Pergamon Press, New York
|
| 34.
|
Eaker, D.,
and Porath, J.
(1967)
J. Microbiol. (Japan)
11,
353-355
|
| 35.
|
Zinn-Justin, S.,
Roumestand, C.,
Gilquin, B.,
Bontems, F.,
Ménez, A.,
and Toma, F.
(1992)
Biochemistry
31,
11335-11347[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Minor, D. L., Jr.,
and Kim, P. S.
(1996)
Nature
380,
730-734[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Lobeck, K.,
Drevet, P.,
Léonetti, M.,
Fromen-Romano, C.,
Ducancel, F.,
Lajeunesse, E.,
Lemaire, C.,
and Ménez, A.
(1998)
Infect. Immun.
66,
418-423[Abstract/Free Full Text]
|
| 38.
|
Hodgson, D.,
Gasparini, S.,
Drevet, P.,
Ducancel, F.,
Bouet, F.,
Boulain, J. C.,
Harris, J. B.,
and Ménez, A.
(1993)
Eur. J. Biochem.
212,
441-446[Medline]
[Order article via Infotrieve]
|
| 39.
|
Danse, J. M.,
Rowan, E. G.,
Gasparini, S.,
Ducancel, F.,
Vatanpour-Young, L. C.,
Poorheidari, G.,
Lajeunesse, E.,
Drevet, P.,
Ménez, R.,
Pinkasfeld, S.,
Boulain, J. C.,
Harvey, A. L.,
and Ménez, A.
(1994)
FEBS Lett.
356,
153-158[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Fiordalisi, J. J.,
Al-Rabiee, R.,
Chiappinelli, V. A.,
and Grant, G. A.
(1994)
Biochemistry
33,
3872-3877[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Bouhaouala-Zahar, B.,
Ducancel, F.,
Zenouaki, I.,
Khalifa, R. B.,
Boorchani, L.,
Pelhate, M.,
Boulain, J. C.,
El Ayeb, M.,
Ménez, A.,
and Karoui, H.
(1996)
Eur. J. Biochem.
238,
653-660[Medline]
[Order article via Infotrieve]
|
| 42.
|
Ducancel, F.,
Boulain, J. C.,
Trémeau, O.,
and Ménez, A.
(1989)
Protein Eng.
3,
139-143[Abstract/Free Full Text]
|
| 43.
|
Boyot, P.,
Pillet, L.,
Ducancel, F.,
Boulain, J. C.,
Trémeau, O.,
and Ménez, A.
(1990)
FEBS Lett.
266,
87-90[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
LaVallie, E. R.,
DiBlasio, E. A.,
Kovacic, S.,
Grant, K. L.,
Schendel, P. F.,
and McCoy, J. M.
(1993)
Bio/Technology
11,
187-193[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Vozza, L. A.,
Wittwer, L.,
Higgins, D. R.,
Purcell, T. J.,
Bergseid, M.,
Collins-Racie, L. A.,
LaVallie, E. R.,
and Hoeffler, J. P.
(1996)
Bio/Technology
14,
77-81[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Ruoppolo, M.,
Moutiez, M.,
Mazzeo, M. F.,
Pucci, P.,
Ménez, A.,
Marino, G.,
and Quéméneur, E.
(1998)
Biochemistry
37,
16060-16068[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Weber, M.,
and Changeux, J. P.
(1974)
Mol. Pharmacol.
10,
1-14[Abstract/Free Full Text]
|
| 48.
|
Boulain, J. C.,
and Ménez, A.
(1982)
Science
217,
732-733[Abstract/Free Full Text]
|
| 49.
|
Trémeau, O.,
Boulain, J. C.,
Couderc, J.,
Fromageot, P.,
and Ménez, A.
(1986)
FEBS Lett.
208,
236-240[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Zinn-Justin, S.,
Pillet, L.,
Ducancel, F.,
Thomas, A.,
Smith, J. C.,
Boulain, J. C.,
and Ménez, A.
(1994)
Protein Eng.
7,
917-923[Abstract/Free Full Text]
|
| 51.
|
Ducancel, F.,
Mérienne, K.,
Fromen-Romano, C.,
Trémeau, O.,
Pillet, L.,
Drevet, P.,
Zinn-Justin, S.,
Boulain, J. C.,
and Ménez, A.
(1996)
J. Biol. Chem.
271,
31345-31353[Abstract/Free Full Text]
|
| 52.
|
Masson, P.,
Froment, M. T.,
Bartels, C. F.,
and Lockridge, O.
(1996)
Eur. J. Biochem.
235,
36-48[Medline]
[Order article via Infotrieve]
|
| 53.
|
Le Du, M. H.,
Ricciardi, A.,
Khayati, M.,
Ménez, R.,
Boulain, J. C.,
Ménez, A.,
and Ducancel, F.
(2000)
J. Mol. Biol.
296,
1017-1026[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Drakopoulou, E.,
Zinn-Justin, S.,
Guenneugues, M.,
Gilquin, B.,
Ménez, A.,
and Vita, C.
(1996)
J. Biol. Chem.
271,
11979-11987 |